According to a new 13G filing with the Securities and Exchange Commission, Bihua Chen‘s Cormorant Asset Management owns 900,000 shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP), which amass 9.7% of the company’s outstanding stock. Gemphire Therapeutics represents a new addition to Cormorant Asset Management’s portfolio.
Gemphire Therapeutics is a clinical-stage biopharmaceutical company engaged in discovering and producing therapeutics to help treat people suffering from dyslipidemia. The company started trading on August 8 and since then its stock has gained 8.7%.
There are no other funds in our database with a known long position in Gemphire Therapeutics Inc. (NASDAQ:GEMP) at this time.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Cormorant Global Healthcare Master Fund||0||748,350||0||748,350||748,350||8.1%|
|Cormorant Global Healthcare GP||0||748,350||0||748,350||748,350||8.1%|
|Cormorant Asset Management||0||900,000||0||900,000||900,000||9.7%|
Page 1 of 8 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Gemphire Therapeutics Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
August 5, 2016
(Date of Event which Requires Filing of this Statement)